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Vascular factors are now established risk factors for cognitive decline, both for dementia and its two main subtypes:
Alzheimer’s disease (AD) and vascular dementia. Their impact likely goes beyond causing an increase in concurrent
vascular pathology, since they have been associated with increasing the risk of degenerative Alzheimer (plaque and
tangle) pathology, either by increasing its rate of formation or reducing elimination from the brain, or a mixture of
the two. A comprehensive series of reviews published in BMC Medicine, investigates the relationship between AD and
cardiovascular diseases and risk factors from a clinical, pathological and therapeutic perspective. Whilst links between
vascular factors and AD have clearly been demonstrated at both the clinical and pathological level, the nature of the
relationship remains to be fully established and there is a lack of high quality treatment studies examining the extent
to which vascular risk modification alters AD disease course. Further longitudinal mechanistic and therapeutic studies
are required, especially to determine whether treatment of vascular risk can prevent or delay the onset of AD and/or
reduce its rate of clinical progression.
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Dementia is a large and growing public health burden,
affecting an estimated 35 million people worldwide with
a prevalence that will double in the next 25 years. Not
surprisingly, it is at the top of governmental priorities for
service development and research, as evidenced by the
recent international governmental G8 summit on dementia
in 2013 and the publication of dementia plans within many
countries. Alzheimer’s disease (AD) remains the most
common cause, responsible for around two-thirds of all
cases, the other major causes being vascular, Lewy body
and fronto-temporal dementias. Treatments for AD,
which provide symptomatic transmitter replacement in
the form of cholinesterase inhibitors and memantine,
have been available for the last 15 years, but these provide
at best modest clinical efficacy, and none convincingly
modify underlying disease course. Since their development
almost 20 years ago, there have been major advances in
our understanding of the molecular pathology of AD [1].
Most research has focused on the overproduction and
abnormal deposition of amyloid (especially ABeta42)
and tau (especially phospho-tau), the two proteins which* Correspondence: john.obrien@medschl.cam.ac.uk
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article, unless otherwise stated.comprise the recognised pathological hallmarks of the
disease, senile plaques and neurofibrillary tangles. Sev-
eral therapeutic attempts to affect underlying disease
processes, based on modifying deposition and/or clearance
of amyloid or tau, are underway, although unfortunately
initial clinical trials, largely around reducing deposition of
amyloid, have been largely negative [2]. This, together with
findings from recent genome wide association studies
which have identified a number of risk genetic variants
with potential influences on vascular and inflammatory
mechanisms [3], has emphasised not only that the full etio-
logical pathway for AD remains to be elucidated, but that
other mechanisms may be equally or more important than
abnormal protein deposition in terms of providing poten-
tially tractable therapeutic targets. Vascular factors and
mechanisms have emerged as an area of key importance.
It has long been recognised that there is a close rela-
tionship between AD and vascular factors [4]. Originally,
this was recognised as a pathological overlap, with an
increased prevalence of vascular lesions – especially
white matter lesions and lacunes – and the finding that
these lower the threshold for the clinical expression of
dementia at a certain burden of Alzheimer pathology
[5,6]. However, it now appears that the relationship goes
much deeper than this. Vascular risk factors, including
hypertension, smoking and hypocholesterolemia are nowentral Ltd. This is an Open Access article distributed under the terms of the
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diagnosis of AD, but for the presence of Alzheimer path-
ology [7]. It has also been demonstrated that Alzheimer
pathology in the form of cerebral amyloidosis can affect
vascular and endothelial function, which may further
impair vascular mechanisms and, potentially, the elimin-
ation of abnormal proteins, such as amyloid, from the
brain [8]. In this timely series of comprehensive review
articles the complex and important relationship between
vascular disease and AD are explored in more detail,
from a pathological, clinical and therapeutic perspective.
Jellinger and Attems [9] provide a detailed account of
the overlap between AD and vascular disease from a
pathological perspective. They highlight that while a
close pathological overlap is well recognised, several key
questions remain unresolved. It is recognised that the
vast majority of (but not all) Alzheimer cases also have
cerebral amyloid angiopathy, and that co-existent cere-
brovasular lesions, primarily subcortical white matter
lesions or lacunes, are common. However, there is not a
good correlation between the two (vascular and degen-
erative pathology) in anatomical co-location, nor is it
clear whether increasing vascular pathology is associated
with increasing severity of degenerative pathology. Evi-
dence to date is reasonably consistent in showing that
minor degrees of vascular pathology, usually subcortical,
are important in lowering the threshold at which a
certain degree of Alzheimer pathology is associated with
dementia. However, in more severe AD cases it appears
that the Alzheimer pathology predominates in terms of
an impact on cognition, and cases of ‘mixed dementia’
more often involve large vessel vascular pathology, such
as cortical infarcts, rather than small vessel disease. This
has very substantial clinical relevance, in that whilst
vascular changes may play a key role in bringing forward
the presentation of AD in those with mixed pathology,
the presence of minor degrees of vascular pathology in
established AD is unlikely to be of clinical significance.
De Bruijn and Ikram [10] discuss the relationship
between both cardiovascular disease and risk factors and
AD from a clinical perspective. They find good evidence
for the relationship between stroke, atrial fibrillation and
coronary heart disease and AD. Stroke is a well recognised
risk factor for dementia, including AD, although the
authors highlight that the relationship between the two
remains unclear and may involve both lowering the
threshold for the expression of dementia in those with
degenerative pathology (as discussed by Jellinger and
Attems [9]) as well as cerebrovascular disease directly
accelerating amyloid production or decreasing its clearance.
Several markers of vascular disease are also associated
with increased AD risk, including intima media thickness,
carotid plaque severity, and large vessel calcification as
measured by computed tomography (CT) scanning. Thereis a stronger relationship between markers of small vessel
disease, including lacunes and white matter lesions, and
AD risk - very much mirroring the pathological overlap
described by Jellinger and Attems. In addition, imaging
has highlighted the potentially deleterious impact of
cerebral microbleeds for both cognitive impairment
and incident AD. This link has biological plausibility,
since both are associated with cerebral amyloidosis,
but as cerebral microbleeds often occur at an increased
rate concurrently with white matter lesion burden and
lacunes, teasing out the specific individual contribu-
tions of different types of subcortical vascular pathology
remains very challenging, especially as they are mea-
sured in different ways [11]. In terms of cardiovascular
risk factors, De Bruijn and Ikram [10] summarise evidence
for the increasingly robust relationship between several
risk factors including hypertension, diabetes, hyperchol-
esterolemia, smoking and obesity and AD, whilst also
suggesting a possible beneficial or protective effect of a
‘Mediterranean’ diet and physical exercise. However, rela-
tionships are complex. For example, while mid-life hyper-
tension has been shown to be a risk factor for AD, the
opposite is true in later life where hypotension in later life
is related to AD, an inconsistency most likely explained
by the effects of Alzheimer’s pathology or dementia in
reducing blood pressure close to the time of disease
onset. There remains controversy as to whether raised
homocysteine levels are a risk factor for AD. Raised
homocysteine has been consistently associated with
increased vascular risk, and has been associated with
brain atrophy and tangle pathology in some studies, but
there are discrepant findings. This relationship is particu-
larly important to determine since raised homocysteine
levels were associated with increased brain volume loss on
serial magnetic resonance imaging (MRI) in those with
mild cognitive impairment in one study [12], and reducing
homocysteine levels through folate and vitamin B12
replacement has been advocated as a potential treat-
ment for AD. The authors also highlight emerging risk
factors, in particular inflammation, chronic kidney disease
and hypothyroidism, all conditions which may be associ-
ated with altered amyloid processing.
Finally, Valenti et al. [13] address perhaps the most
critical and clinically important question, which is, given
the clear overlap between vascular factors and AD, does
the treatment of vascular risk in those with AD provide
any benefit, either in terms of improvement or, more
likely, decreasing the rate of subsequent cognitive decline?
Perhaps surprisingly, the answer to this question is far
from clear, despite the fact that the authors review 14
observational studies and 11 randomised controlled trials.
Some observational studies suggest that enhanced treat-
ment of vascular risk using a multifactorial approach,
including the treatment of hypertension and statin
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suffer from potential bias. Randomised controlled trials
are relatively few in number, often of modest size with
a short duration of follow-up which, while appropriate
for cardiovascular outcomes, is insufficient for deter-
mining longer term cognitive outcomes. Indeed, several of
the studies were primarily set up to assess cardiovascular
outcomes, and when these end points were met the trials
were stopped [14]. The only randomised controlled trial
examining the effectiveness of a vascular care package
compared to placebo did find significant differences
between groups in the expected direction in terms of
lower homocysteine and cholesterol in the actively treated
group, but no impact on cognitive end points [15]. There
have been surprisingly few controlled studies in other
areas – none of antihypertensive treatment compared with
placebo in established AD and several small and one large
trial of a statin [16], which did not find a benefit of atorva-
statin compared to placebo in a 72 week study of those
with mild to moderate AD. The authors conclude that
until the evidence base is stronger it remains a reasonable
option to treat vascular risk factors in AD, particularly in
those with co-existent cardiovascular disease, a view sup-
ported by consensus Guidelines [17], but the authors call
for large adequately powered trials, both in mild cognitive
impairment and the early stages of AD, to determine
whether treating vascular risk factors delays progression
in those without overt cerebrovascular disease. As guest
editors of this series of articles, we very much concur with
this view and also with Valenti et al’s [13] conclusion that
the outcomes of such studies would potentially have a
major impact on the way AD is assessed and treated, both
in primary and secondary care.
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